← Eichor
Study identifier: NCT07733505 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Normethermic Intraperitoneal Chemotherapy - a Novel Concept for Local Treatment of the Elderly and Fragile Women With Advanced Ovarian Cancer?

Condition: Ovarian Cancer  ·  Sponsor: Odense University Hospital

PhasePhase 1
Planned participants10
Who can joinFemale, 70 Years to no upper limit
Healthy volunteersNo

About this study

The purpose of this feasibility study is to investigate whether NIPEC with carboplatin after surgery is safe for the elderly and frail women with advanced ovarian cancer. To achieve this, women with advanced ovarian cancer who receive surgery followed by NIPEC will be closely monitored in the period after treatment. We will assess complications, side effects, recovery after surgery and NIPEC, and whether standard chemotherapy can be started on time and completed as planned. In addition, participants will be followed for six months using questionnaires and interviews to evaluate patient-reported outcomes, including quality of life. In the more technical assessment of NIPEC, carboplatin tissue pharmacokinetics and inflammatory responses during and after NIPEC will be analysed using microdialysis and histology.

This description comes directly from the study's public registry record.

Talk to the study team

Lone LKP Kjeld Petersen, MD, DMSc  ·  +4528968856  ·  lone.kjeld.petersen@rsyd.dk

Always discuss trial participation with your own doctor first.

Locations (1)

Odense University HospitalOdense, DenmarkRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07733505